Support online!
Alterme 15 mg / 3 mL Pen Semaglutide is an injectable medication designed to support the treatment of type-2 diabetes and assist with long-term weight management. The product contains semaglutide, a GLP-1 receptor agonist that helps regulate blood glucose levels and reduce appetite. Alterme is developed by Zydus Lifesciences and is expected to become one of the new semaglutide options available as the market expands.
Semaglutide works by mimicking the activity of a natural hormone called glucagon-like peptide-1 (GLP-1). This hormone plays an important role in controlling blood sugar after meals. By stimulating insulin release when glucose levels rise and reducing excess glucagon production, semaglutide helps improve overall glucose balance. In addition, the medication slows gastric emptying and promotes a feeling of fullness, which can help patients reduce calorie intake and support weight management.
Alterme is supplied in a prefilled multi-dose pen containing 15 mg of semaglutide in 3 mL of solution. The pen is designed to allow flexible weekly dosing, enabling patients to gradually increase the amount of medication depending on their treatment plan. Because semaglutide has a long half-life, the medication is typically administered once per week through a subcutaneous injection.
The injection is placed under the skin in common areas such as the abdomen, thigh, or upper arm. Patients are usually advised to use the medication on the same day each week for consistent results. The adjustable pen allows multiple doses to be delivered from the same cartridge, making it convenient for dose adjustments during therapy.
Treatment with Alterme generally follows a gradual dose-escalation schedule. Starting with a lower dose helps the body adapt to the medication and can reduce gastrointestinal side effects. A typical dosing progression may begin with 0.25 mg once weekly for the first four weeks. After the initial period, the dose is often increased to 0.5 mg once weekly. Depending on individual treatment goals and physician recommendations, the dosage may later be raised to 1 mg per week.
For some patients, particularly those using semaglutide for weight management, the dose may be further increased over time. Additional titration steps may include 1.7 mg weekly and eventually up to 2 mg or 2.4 mg weekly, depending on medical guidance and treatment response.
The Alterme 15 mg / 3 mL semaglutide pen is designed to simplify treatment by allowing dose adjustments without requiring a new device for each dosage level. This approach can improve convenience and help patients maintain consistent therapy over the long term.
As with all prescription medications, Alterme should be used under the supervision of a qualified healthcare professional. Proper medical guidance ensures that dosing is tailored to the patient’s health profile and treatment objectives, while also helping monitor progress and potential side effects throughout the therapy.